Your browser doesn't support javascript.
A Study to Assess the Safety and Efficacy of CoroQuil-Zn 750 in Comparison to the Standard of Care for the Treatment of Mild to Moderate COVID-19.
CTRI; 11-12-2020; TrialID: CTRI/2020/12/029735
Clinical Trial Register | ICTRP | ID: ictrp-CTRI202012029735
ABSTRACT

Condition

Health Condition 1 B972- Coronavirus as the cause of diseases classified elsewhere

Intervention

Intervention1 CoroQuil-Zn 750mg 750mg x 2, administered orally three times a day for 14 days
Control Intervention1 COVID Standard Care As per the sites COVID SOP


Primary 

outcome:

Negative result for qRT-PCR testing for COVIDTimepoint 14 days

Criteria

Inclusion criteria 1. Written signed and dated informed consent (patient or LAR).

2. Both genders, aged >=18 to <=75 years,

3. Patients with RT-qPCR confirmed COVID-19 patients

4. SpO2>=90% and respiratory rate <=30/minute

5. Healthy adult patients with ASA I to II

6. A score of between 3 to 5 on the Modified WHO Ordinal Scale for Clinical Improvement (refer protocol appendix 23.1)

7. Patients who agree to abide by the study requirements



Exclusion criteria 1. Pregnant and lactating women

2. Children <18 yrs. of age; elderly >75 years

3. SpO2 <90% for adults and respiratory rate >30/minute

4. Patients having persistent nausea/vomiting

5. Need for direct admission to the intensive care unit for mechanical ventilation

6. Underlying chronic obstructive pulmonary disease stage III-IV

7. Patients simultaneously participating in another clinical study.

8. History of stroke with significant neurologic deficit.

9. Patients with any concurrent pre-existing severe/uncontrolled, clinically significant systemic disease [e.g. heart failure (NYHA 2 or above)], cancer, liver disease, kidney disease or anaemia etc.) that, in the opinion of investigator precludes the subject´s participation in the study or interferes with the interpretation of the study results.

10. Patients with history of serology tests positive for hepatitis B, hepatitis C, or human immunodeficiency virus.

11. Medical or psychological conditions deemed by the investigators to interfere with successful participation in the study

12. A subject who is judged by the investigator as inappropriate to participate in the study for any reason other than those mentioned above.

Collection: Clinical trial registers Database: ICTRP Year: 2020 Document Type: Clinical Trial Register

Similar

MEDLINE

...
LILACS

LIS

Collection: Clinical trial registers Database: ICTRP Year: 2020 Document Type: Clinical Trial Register